Peng Huitong, Wu Hongyi, Zhang Ge, Zhang Wei, Guo Yifan, Chang Lin, Chen She, Xue Ruyi, Zhang Si
Department of Biochemistry and Molecular Biology, NHC Key Laboratory of Glycoconjugates Research, School of Basic Medical Sciences, Fudan University, Shanghai, People's Republic of China.
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Int J Gen Med. 2020 Oct 9;13:791-802. doi: 10.2147/IJGM.S275481. eCollection 2020.
Little is known about the relationship between the level of platelet NOD-like receptor protein 3 (NLRP3) and the severity of acute coronary syndrome (ACS) or the prognostic value of platelet NLRP3 for percutaneous coronary intervention (PCI).
Platelets collected from 25 healthy subjects, 23 patients with stable angina pectoris (SAP), and 72 patients with ACS were analyzed by Western blotting and real-time fluorescence quantitative PCR (qPCR). A total of 152 patients with ACS who had undergone PCI were included in this study to evaluate the prognostic value of platelet .
The levels of platelet in both the healthy and SAP groups were clearly lower than in the ACS group (<0.001). According to the Pearson correlation analysis, the expression of platelet was closely related to the mean platelet volume (MPV), left ventricular ejection fraction (LVEF), the Gensini score, and the Global Registry of Acute Coronary Events (GRACE) score (all <0.001). Multivariate logistic regression analysis identified as an independent risk factor for adverse cardiovascular events (ACEs) after PCI (=0.004). The proportion of patients with high expression (the -high group) remaining free of adverse events for 3 years was remarkably lower than that in patients with low expression (the -low group; =0.024). The -high group had a significantly higher proportion of patients with interleukin-1β-expressing (20.4%±6.1%) platelets than the -low group (10.7%±3.5%, <0.001). Moreover, the -high group exhibited higher platelet activity, as indicated by increased PAC-1 binding and CD62P expression, compared with the -low group (<0.001).
These results indicated that platelet was a novel potential prognostic factor for patients with ACS that underwent PCI.
关于血小板NOD样受体蛋白3（NLRP3）水平与急性冠状动脉综合征（ACS）严重程度之间的关系，以及血小板NLRP3对经皮冠状动脉介入治疗（PCI）的预后价值，目前所知甚少。
采用蛋白质免疫印迹法和实时荧光定量聚合酶链反应（qPCR）对25名健康受试者、23名稳定型心绞痛（SAP）患者和72名ACS患者采集的血小板进行分析。本研究共纳入152例接受PCI的ACS患者，以评估血小板的预后价值。
健康组和SAP组的血小板水平均明显低于ACS组（<0.001）。根据Pearson相关性分析，血小板的表达与平均血小板体积（MPV）、左心室射血分数（LVEF）、Gensini评分和急性冠状动脉事件全球注册（GRACE）评分密切相关（均<0.001）。多因素逻辑回归分析确定为PCI术后不良心血管事件（ACEs）的独立危险因素（=0.004）。高表达患者（高组）3年无不良事件的比例明显低于低表达患者（低组；=0.024）。高组中表达白细胞介素-1β的血小板患者比例（20.4%±6.1%）明显高于低组（10.7%±3.5%，<0.001）。此外，与低组相比，高组表现出更高的血小板活性，表现为PAC-1结合和CD62P表达增加（<0.001）。
这些结果表明，血小板是接受PCI的ACS患者的一种新的潜在预后因素。
